Spots Global Cancer Trial Database for Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
Official Title: An Open-Label, Single-Arm, Multicenter Phase 1 Study Evaluating the Safety and Pharmacokinetics of Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
Study ID: NCT02598570
Conditions
Interventions
Study Description
Brief Summary: This study seeks to evaluate the safety and pharmacokinetics of duvelisib in Japanese participants with relapsed or refractory lymphoma.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Site Reference ID/Investigator# 141826, Aichi, , Japan
Site Reference ID/Investigator# 141595, Fukuoka, , Japan
Site Reference ID/Investigator# 141594, Tokyo, , Japan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
